RU2166320C2 - Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии - Google Patents

Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии Download PDF

Info

Publication number
RU2166320C2
RU2166320C2 RU95117068/14A RU95117068A RU2166320C2 RU 2166320 C2 RU2166320 C2 RU 2166320C2 RU 95117068/14 A RU95117068/14 A RU 95117068/14A RU 95117068 A RU95117068 A RU 95117068A RU 2166320 C2 RU2166320 C2 RU 2166320C2
Authority
RU
Russia
Prior art keywords
substituted
group
oxo
tetrahydro
hypertriglyceridemia
Prior art date
Application number
RU95117068/14A
Other languages
English (en)
Russian (ru)
Other versions
RU95117068A (ru
Inventor
Сугияма Ясуо
Юкимаса Хидефуми
Original Assignee
Такеда Кемикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Кемикал Индастриз, Лтд. filed Critical Такеда Кемикал Индастриз, Лтд.
Publication of RU95117068A publication Critical patent/RU95117068A/ru
Application granted granted Critical
Publication of RU2166320C2 publication Critical patent/RU2166320C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU95117068/14A 1994-10-07 1995-10-06 Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии RU2166320C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07
JP06-244136 1994-10-07

Publications (2)

Publication Number Publication Date
RU95117068A RU95117068A (ru) 1998-01-10
RU2166320C2 true RU2166320C2 (ru) 2001-05-10

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95117068/14A RU2166320C2 (ru) 1994-10-07 1995-10-06 Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии

Country Status (11)

Country Link
EP (1) EP0705607A2 (enrdf_load_stackoverflow)
KR (1) KR960013370A (enrdf_load_stackoverflow)
CN (1) CN1128657A (enrdf_load_stackoverflow)
AU (1) AU703422B2 (enrdf_load_stackoverflow)
CA (1) CA2160092A1 (enrdf_load_stackoverflow)
FI (1) FI954773A7 (enrdf_load_stackoverflow)
HU (1) HUT73422A (enrdf_load_stackoverflow)
NO (1) NO308580B1 (enrdf_load_stackoverflow)
NZ (1) NZ280165A (enrdf_load_stackoverflow)
RU (1) RU2166320C2 (enrdf_load_stackoverflow)
TW (1) TW401301B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2271808C2 (ru) * 2001-06-06 2006-03-20 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и жирнокислотный сложный эфир сахарозы

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) * 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
DE69637603D1 (de) * 1995-09-13 2008-08-28 Takeda Pharmaceutical 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische Mittel
CN1198100A (zh) * 1996-06-11 1998-11-04 佐纳根有限公司 聚氨基葡糖药物投递系统
EP0979227B1 (en) 1997-04-21 2005-11-16 Takeda Pharmaceutical Company Limited 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
SK7522001A3 (en) 1998-03-31 2002-02-05 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU5588400A (en) 1999-05-26 2000-12-18 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
WO2001010846A2 (en) * 1999-08-05 2001-02-15 Igt Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
CN1473053A (zh) * 2000-11-09 2004-02-04 ����ҩƷ��ҵ��ʽ���� 高密度脂蛋白-胆甾醇含量提高剂
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CA2514547A1 (en) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090118255A1 (en) * 2004-08-09 2009-05-07 Takeda Pharmaceutical Company Limited Crp Lowering Agent
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP2146722A4 (en) 2007-05-10 2011-08-03 Amr Technology Inc ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
BR112022022530A2 (pt) 2020-05-05 2023-02-23 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
CN115916754A (zh) 2020-05-05 2023-04-04 纽威伦特公司 杂芳族大环醚化学治疗剂
KR20240087788A (ko) 2021-10-01 2024-06-19 뉴베일런트, 아이엔씨. 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153190A (en) * 1990-03-08 1992-10-06 Adir Et Compagnie Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
EP0579222A2 (en) * 1992-07-17 1994-01-19 Senju Pharmaceutical Co., Ltd. Lipid metabolism improving composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48855A1 (en) * 1992-04-20 1998-05-18 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU1589895A (en) * 1994-02-09 1995-08-29 Takeda Chemical Industries Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5153190A (en) * 1990-03-08 1992-10-06 Adir Et Compagnie Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines
EP0579222A2 (en) * 1992-07-17 1994-01-19 Senju Pharmaceutical Co., Ltd. Lipid metabolism improving composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, 1986, ч.2, с.90. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2271808C2 (ru) * 2001-06-06 2006-03-20 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и жирнокислотный сложный эфир сахарозы

Also Published As

Publication number Publication date
HUT73422A (en) 1996-07-29
TW401301B (en) 2000-08-11
KR960013370A (ko) 1996-05-22
AU703422B2 (en) 1999-03-25
NO953961D0 (no) 1995-10-05
EP0705607A2 (en) 1996-04-10
CN1128657A (zh) 1996-08-14
AU3308195A (en) 1996-04-18
EP0705607A3 (enrdf_load_stackoverflow) 1996-05-08
HU9502918D0 (en) 1995-11-28
FI954773A0 (fi) 1995-10-06
CA2160092A1 (en) 1996-04-08
NO308580B1 (no) 2000-10-02
FI954773A7 (fi) 1996-04-08
NO953961L (no) 1996-04-09
NZ280165A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
RU2166320C2 (ru) Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии
EP0862562B1 (en) Benzoxazepine compounds, their production and use as lipid lowering agents
US20080132483A1 (en) Agent for preventing or treating organ functional disorders and organ dysfunction
EP0645377B1 (en) Benzoxazepine derivatives useful as squalene synthetase inhibitors
CA2231052C (en) Benzoxazepine compounds, their production and use as lipid lowering agents
EP0567026A1 (en) 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
JPWO2007102531A1 (ja) 併用薬
US20080058310A1 (en) High-density lipoprotein-cholesterol level elevating agent
US20090209510A1 (en) Novel Method of Treating Hyperlipidemia
US20080113965A1 (en) Skeletal muscle protecting agent
JP3479796B2 (ja) ベンゾオキサゼピン化合物
JP4138299B2 (ja) 高密度リポタンパク−コレステロール上昇剤
JPH08157369A (ja) トリグリセライド低下剤
US20090118255A1 (en) Crp Lowering Agent
JPH0987260A (ja) 縮合環化合物とその用途
JP4021612B2 (ja) ベンゾオキサゼピン化合物
JP3764180B2 (ja) 縮合環化合物とその用途
JP2004315500A (ja) 骨格筋保護剤
JP2007332154A (ja) ベンゾオキサゼピン化合物
KR20080015395A (ko) 황색종 치료제